Sessa C, Calabresi F, Cavalli F, Cerny T, Liati P, Skovsgaard T, Sorio R, Kaye S B
Ospedale San Giovanni, Bellinzona, Switzerland.
Ann Oncol. 1991 Nov-Dec;2(10):727-31. doi: 10.1093/oxfordjournals.annonc.a057851.
The new anthracycline analogue, 4'-iodo-4'-deoxydoxorubicin (I-DOX), was administered at 70 mg/m2 as first chemotherapy in 61 patients with advanced NSCL (19), colon (20) and breast cancers (22). Treatment was repeated every 3 weeks; the dose was decreased to 60 mg/m2 (19% of the cycles) or increased to 80 mg/m2 (17% of the cycles) according to the granulocyte count nadir. Partial responses were observed in 6% of the patients with NSCL, in 5.5% of those with colon and in 10% of those with breast cancers. The main toxicity was a selective granulocytopenia characterized by a duration of about 1 week, and a high inter-patient variability. Non-haematological toxicities were mild. The negative results obtained in breast cancer might be related to the dose administered. Further studies in this tumour type should be performed with a more aggressive schedule.
新型蒽环类类似物4'-碘-4'-脱氧阿霉素（I-DOX）以70mg/m²的剂量作为一线化疗药物，应用于61例晚期非小细胞肺癌（19例）、结肠癌（20例）和乳腺癌（22例）患者。每3周重复治疗一次；根据粒细胞计数最低点，剂量可降至60mg/m²（19%的疗程）或增至80mg/m²（17%的疗程）。非小细胞肺癌患者中有6%、结肠癌患者中有5.5%、乳腺癌患者中有10%观察到部分缓解。主要毒性为选择性粒细胞减少，持续时间约1周，且患者间差异较大。非血液学毒性较轻。乳腺癌患者获得的阴性结果可能与给药剂量有关。对此肿瘤类型应采用更积极的方案进行进一步研究。
